Pfizer's stock has recently struggled but remains a bargain with generous dividends. Is now a good time to invest in PFE?

It's worth noting that Biohaven has just reported that sales of Nurtec ODT came in at $124 million in the first quarter – below analyst projections and the $190 million made in the last quarter ...

The Department of Justice (DoJ) claims that Biohaven – before being acquired by Pfizer – paid "improper remuneration" to some Nurtec ODT (rimegepant) prescribers in the form of speaker fees ...

With the popular social media app once again at risk of going dark, there are best practices pharma brands can use on other platforms.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

They include migraine therapy Nurtec ODT (gained through its 2022 acquisition of Biohaven) and cancer drug Padcev (picked up via Pfizer's 2023 buyout of Seagen). Pfizer has also invested heavily ...

Pfizer's growth is boosted by Nurtec ODT, acquired from Biohaven and Padcev from the Seagen acquisition. By 2030, Pfizer aims to add $25 billion to its top line. Pfizer has already boosted its ...

Of late, pharmaceutical behemoth Pfizer Inc.’s PFE stock has struggled, but it remains a bargain with generous dividends. Its financials aren’t in bad shape either. So, is it the right time to bet on ...